サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1356890

嚢胞性線維症市場レポート：2030年までの動向、予測、競合分析

Cystic Fibrosis Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

嚢胞性線維症市場レポート：2030年までの動向、予測、競合分析
出版日: 2023年09月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

嚢胞性線維症の動向と予測

嚢胞性線維症の世界市場は、2024年から2030年までのCAGRが8.6%で、2030年までに推定109億米ドルに達すると予想されます。この市場の主な促進要因は、ゲノム変異例の増加、経口治療に対する患者の嗜好の高まり、パイプライン患者の増加です。嚢胞性線維症の世界市場の将来性は、小売薬局・ドラッグストア、オンライン薬局、病院薬局の各市場における機会によって有望視されています。

嚢胞性線維症市場の洞察

Lucintelの予測では、嚢胞性線維症膜貫通コンダクタンス制御薬は、細胞身体機能の改善、患者のQOL向上、肺炎や呼吸器症状の軽減を目的とした用途の拡大により、予測期間中に最も高い成長が見込まれています。

オンライン薬局は予測期間中に最も高い成長が見込まれます。

北米は、様々な呼吸器疾患患者の増加、継続的なヘルスケアインフラの進歩、主要プレイヤーの存在により、予測期間中に最も高い成長が見込まれます。

本レポートでは、以下の11の主要な質問に回答している：

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
  • Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
  • Q.3.今後成長が加速すると思われる地域とその理由は？
  • Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
  • Q.5.この市場におけるビジネスリスクと競合の脅威は？
  • Q.6.この市場における新たな動向とその理由は？
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は？
  • Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界の嚢胞性線維症市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界の嚢胞性線維症市場の動向（2018-2023）と予測（2024-2030）
  • 薬剤クラス別の世界の嚢胞性線維症市場
    • 嚢胞性線維症の膜貫通コンダクタンス調節装置
    • 気管支拡張薬
    • 粘液溶解性
    • 膵臓酵素サプリメント
    • その他
  • 投与経路別の世界の嚢胞性線維症市場
    • オーラル
    • 非経口
  • 最終用途別の世界の嚢胞性線維症市場
    • 小売薬局およびドラッグストア
    • オンライン薬局
    • 病院薬局
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界の嚢胞性線維症市場
  • 北米の嚢胞性線維症市場
  • 欧州の嚢胞性線維症市場
  • アジア太平洋嚢胞性線維症市場
  • その他地域嚢胞性線維症市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略分析

  • 成長機会分析
    • 薬剤クラス別の世界の嚢胞性線維症市場の成長機会
    • 投与経路別の世界の嚢胞性線維症市場の成長機会
    • 最終用途別の世界の嚢胞性線維症市場の成長機会
    • 地域別の世界の嚢胞性線維症市場の成長機会
  • 世界の嚢胞性線維症市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の嚢胞性線維症市場の能力拡大
    • 世界の嚢胞性線維症市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Gilead Sciences
  • Vertex Pharmaceuticals
  • Novartis
  • Allergan
  • AbbVie
  • Teva Pharmaceutical Industries
  • F. Hoffmann-La Roche
  • Pharmaxis
  • Mylan
  • GlaxoSmithKline
目次

Cystic Fibrosis Trends and Forecast

The future of the global cystic fibrosis market looks promising with opportunities in the retail pharmacy & drug store, online pharmacy, and hospital pharmacy markets. The global cystic fibrosis market is expected to reach an estimated $10.9 billion by 2030 with a CAGR of 8.6% from 2024 to 2030. The major drivers for this market are growing cases of genomic mutations, rising patients preference for oral treatment, and augmenting number of pipeline patients.

A more than 150-page report is developed to help in your business decisions.

Cystic Fibrosis by Segment

The study includes a forecast for the global cystic fibrosis by drug class, route of administration, end use, and region.

Cystic Fibrosis Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
  • Bronchodilators
  • Mucolytic
  • Pancreatic Enzyme Supplement
  • Others

Cystic Fibrosis Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Oral
  • Parenteral

Cystic Fibrosis Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Retail Pharmacies & Drug Stores
  • Online Pharmacies
  • Hospital Pharmacies
  • Others

Cystic Fibrosis Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cystic Fibrosis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cystic fibrosis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cystic fibrosis companies profiled in this report include-

  • Gilead Sciences
  • Vertex Pharmaceuticals
  • Novartis
  • Allergan
  • Abbvie
  • Teva Pharmaceutical Industries
  • F. Hoffmann-La Roche
  • Pharmaxis
  • Mylan
  • Glaxosmithkline

Cystic Fibrosis Market Insights

Lucintel forecasts that cystic fibrosis transmembrane conductance regulator is expected to witness highest growth over the forecast period due to its expanding use to improve cellular body function, enhance patients' quality of life, and lessen lung flare-ups and respiratory symptoms.

Online pharmacy is expected to witness highest growth over the forecast period.

North America is expected to witness highest growth over the forecast period due to increasing number of people with various respiratory diseases, continous healthcare infrastructural advancement, and presence of key players in the region.

Features of the Global Cystic Fibrosis Market

Market Size Estimates: Cystic fibrosis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cystic fibrosis market size by various segments, such as by route of administration, end use, and region. in terms of value ($B).

Regional Analysis: Cystic fibrosis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different route of administrations, end uses, and region.s for the cystic fibrosis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cystic fibrosis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the cystic fibrosis market size?

Answer: The global cystic fibrosis market is expected to reach an estimated $10.9 billion by 2030.

Q.2. What is the growth forecast for cystic fibrosis market?

Answer: The global cystic fibrosis market is expected to grow with a CAGR of 8.6% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the cystic fibrosis market?

Answer: The major drivers for this market are growing cases of genomic mutations, rising patients preference for oral treatment, and augmenting number of pipeline patients.

Q.4. What are the major segments for cystic fibrosis market?

Answer: The future of the cystic fibrosis market looks promising with opportunities in the retail pharmacy & drug store, online pharmacy, and hospital pharmacy markets.

Q.5. Who are the key cystic fibrosis market companies?

Answer: Some of the key cystic fibrosis companies are as follows:

  • Gilead Sciences
  • Vertex Pharmaceuticals
  • Novartis
  • Allergan
  • AbbVie
  • Teva Pharmaceutical Industries
  • F. Hoffmann-La Roche
  • Pharmaxis
  • Mylan
  • GlaxoSmithKline

Q.6. Which cystic fibrosis market segment will be the largest in future?

Answer: Lucintel forecasts that cystic fibrosis transmembrane conductance regulator is expected to witness highest growth over the forecast period due to its expanding use to improve cellular body function, enhance patients' quality of life, and lessen lung flare-ups and respiratory symptoms.

Q.7. In cystic fibrosis market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to increasing number of people with various respiratory diseases, continous healthcare infrastructural advancement, and presence of key players in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cystic fibrosis market by drug class (cystic fibrosis transmembrane conductance regulator (CFTR), bronchodilators, mucolytic, pancreatic enzyme supplement, and others), route of administration (oral and parenteral), end use (retail pharmacies & drug stores, online pharmacies, hospital pharmacies, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cystic Fibrosis Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cystic Fibrosis Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cystic Fibrosis Market by Drug Class
    • 3.3.1: Cystic Fibrosis Transmembrane Conductance Regulator
    • 3.3.2: Bronchodilators
    • 3.3.3: Mucolytic
    • 3.3.4: Pancreatic Enzyme Supplement
    • 3.3.5: Others
  • 3.4: Global Cystic Fibrosis Market by Route of Administration
    • 3.4.1: Oral
    • 3.4.2: Parenteral
  • 3.5: Global Cystic Fibrosis Market by End Use
    • 3.5.1: Retail Pharmacies & Drug Stores
    • 3.5.2: Online Pharmacies
    • 3.5.3: Hospital Pharmacies
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cystic Fibrosis Market by Region
  • 4.2: North American Cystic Fibrosis Market
    • 4.2.2: North American Cystic Fibrosis Market by End Use: Retail Pharmacies & Drug Stores, Online Pharmacies, Hospital Pharmacies, and Others
  • 4.3: European Cystic Fibrosis Market
    • 4.3.1: European Cystic Fibrosis Market by Drug Class: Cystic Fibrosis Transmembrane Conductance Regulator, Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and Others
    • 4.3.2: European Cystic Fibrosis Market by End Use: Retail Pharmacies & Drug Stores, Online Pharmacies, Hospital Pharmacies, and Others
  • 4.4: APAC Cystic Fibrosis Market
    • 4.4.1: APAC Cystic Fibrosis Market by Drug Class: Cystic Fibrosis Transmembrane Conductance Regulator, Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and Others
    • 4.4.2: APAC Cystic Fibrosis Market by End Use: Retail Pharmacies & Drug Stores, Online Pharmacies, Hospital Pharmacies, and Others
  • 4.5: ROW Cystic Fibrosis Market
    • 4.5.1: ROW Cystic Fibrosis Market by Drug Class: Cystic Fibrosis Transmembrane Conductance Regulator, Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and Others
    • 4.5.2: ROW Cystic Fibrosis Market by End Use: Retail Pharmacies & Drug Stores, Online Pharmacies, Hospital Pharmacies, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cystic Fibrosis Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Cystic Fibrosis Market by Route of Administration
    • 6.1.3: Growth Opportunities for the Global Cystic Fibrosis Market by End Use
    • 6.1.4: Growth Opportunities for the Global Cystic Fibrosis Market by Region
  • 6.2: Emerging Trends in the Global Cystic Fibrosis Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cystic Fibrosis Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cystic Fibrosis Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Gilead Sciences
  • 7.2: Vertex Pharmaceuticals
  • 7.3: Novartis
  • 7.4: Allergan
  • 7.5: AbbVie
  • 7.6: Teva Pharmaceutical Industries
  • 7.7: F. Hoffmann-La Roche
  • 7.8: Pharmaxis
  • 7.9: Mylan
  • 7.10: GlaxoSmithKline